Dr. Katherine Meng represents pharmaceutical and biotech companies on the procurement and protection of intellectual property. Kate prosecutes patents and manages patent portfolios worldwide for clients and coordinates strategies to meet clients' IP needs and business goals. She also advises clients regarding patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios in connection with venture capital and private equity financings, collaborations, and/or partnering deals.
Kate has worked with established companies, start-ups, and research institutions. She has experience with a wide range of technologies, including immunotherapy (e.g., antibodies, antibody drug conjugates, vaccines, cell-based therapies, CAR-T cell technology, and immune checkpoint modulators), gene therapy, cancer treatment, virology, stem cells, neurological disorder therapeutics, diagnostic assays, and therapeutic polypeptides.
Prior to joining Jones Day in 2020, Kate obtained her Ph.D. in molecular cell and developmental biology. She has authored several peer-reviewed publications and has served in several leadership roles throughout her academic studies.
Expérience
- The George Washington University (J.D. with honors 2020; Thurgood Marshall Scholar); University of Miami (Ph.D. in Molecular Cell and Developmental Biology 2017); China Pharmaceutical University (B.S. in Traditional Chinese Pharmacy 2011)
- California
- Judicial intern to Judge Evan J. Wallach, U.S. Court of Appeals, Federal Circuit (Spring 2019)